EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study

Yuki Shimizu iD, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki-Asano Mori, Atsushi Wake und 3 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yuki Shimizu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Toranomon Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mantle cell lymphoma is considered an aggressive B‐cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies.

Method

Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) and rituximab, bendamustine, and cytarabine (R‐BAC) at Toranomon Hospital between November 2016 and February 2022.

Result

Although one patient discontinued R‐BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high‐dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow‐up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non‐hematological AEs specific to R‐BAC.

Conclusion

R‐CHOP/R‐BAC may be a good induction therapy for transplant‐eligible patients with mantle cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellHematopoietic Stem Cell TransplantationAdultHumansRituximabRetrospective StudiesBendamustine HydrochlorideAntineoplastic Combined Chemotherapy ProtocolsTransplantation, AutologousCyclophosphamidePrednisoneVincristineCytarabineDoxorubicin

Stichwörter der Autor:innen

effective and safeinduction therapymantle cell lymphomarituximab/bendamustine/cytarabinetransplant eligibility

Substanzen

RituximabBendamustine HydrochlorideCyclophosphamidePrednisoneVincristineCytarabineDoxorubicin

Autor:innen und Institutionen

  • Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Department of Hematology, Toranomon Hospital, Kajigaya, Japan.

ORCID-Profile: Yuki Shimizu

Zitieren

APA

Shimizu, Y., Kaji, D., Watanabe, O., Yamaguchi, K., Kageyama, K., Taya, Y., Nishida, A., Ishiwata, K., Takagi, S., Yamamoto, H., Mori, Y. A., Wake, A., Uchida, N., Taniguchi, S., & Yamamoto, G. (2023). Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.6114

Vancouver

Shimizu Y, Kaji D, Watanabe O, Yamaguchi K, Kageyama K, Taya Y, et al. Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study. Cancer Medicine. 2023. doi:10.1002/cam4.6114

BibTeX
@article{Shimizu2023,
  author = {Shimizu, Yuki and Kaji, Daisuke and Watanabe, Otoya and Yamaguchi, Kyosuke and Kageyama, Kosei and Taya, Yuki and Nishida, Aya and Ishiwata, Kazuya and Takagi, Shinsuke and Yamamoto, Hisashi and Mori, Yuki-Asano and Wake, Atsushi and Uchida, Naoyuki and Taniguchi, Shuichi and Yamamoto, Go},
  title = {Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6114}
}
Kostenlos starten →